Each week the MPR team brings you the top stories from the world of medicine and pharma in a matter of minutes. With 35 years of publishing drug information behind us, you can rely on MPR to provide accurate and up-to-date news.
…
continue reading
1
Illegal Online Pharmacies: An interview with Libby Baney, senior advisor to the Alliance for Safe Online Pharmacies
25:08
25:08
Spela senare
Spela senare
Listor
Gilla
Gillad
25:08
Libby Baney, Senior Advisor to ASOP Global and a partner at Faegre Drinker Consulting, talks to MPR about the current state of online pharmacies and what is being done to protect patients.
…
continue reading
1
MPR Weekly Dose Podcast #219 — Hurricane Helene Impacts IV Supply; At-Home COVID/Flu Test; Fake Online Pharmacies; Depression Tx Fast Tracked; Cologuard Plus Cleared
11:28
11:28
Spela senare
Spela senare
Listor
Gilla
Gillad
11:28
Supplies of a significant number of IV solutions have been impacted by Hurricane Helene; First at-home COVID-19/Flu over-the-counter antigen test gains market authorization; DOJ clamp down on fake online pharmacies; Investigational therapy Fast Tracked for treatment resistant depression; and Cologuard Plus gets cleared for colorectal cancer screeni…
…
continue reading
1
MPR Weekly Dose Podcast #218 — Novel Weight Management Tx; Complete Response Letter for Tradipitant; Apple’s Sleep Apnea Feature Cleared; New Keytruda Indication; Ebglyss for Atopic Dermatitis
13:18
13:18
Spela senare
Spela senare
Listor
Gilla
Gillad
13:18
The FDA clears capsule that creates sensation of fullness in the stomach; Complete Response Letter issued for gastroparesis treatment; Apple’s sleep apnea notification feature gets clearance; Keytruda gains malignant pleural mesothelioma indication; Ebglyss approved for atopic dermatitis
…
continue reading
1
MPR Weekly Dose Podcast #217 — Novel Ulcerative Colitis Tx; Once-Weekly Insulin Efsitora in T1D; Dupilumab for Urticaria; Ultra-Long Acting Biologic in Asthma; Results for Herpes Vaccine
12:21
12:21
Spela senare
Spela senare
Listor
Gilla
Gillad
12:21
New drug approved to treat ulcerative colitis; Once-weekly insulin efsitora investigated in type 1 diabetes; Dupilumab shows efficacy for treating urticaria; A twice-yearly injection shows potential for treating severe asthma; and GSK calls an end to their development of a herpes vaccine.
…
continue reading
1
MPR Weekly Dose Podcast #216 — Vaccine Guidance for Flu Season; Mpox Vaccine; Updated Novavax Vaccine Authorization; OTC Gel for ED; New Insertion Device for Paragard
12:46
12:46
Spela senare
Spela senare
Listor
Gilla
Gillad
12:46
CDC Advisory Committee issue vaccine guidelines for flu season; Smallpox vaccine gains expanded indication; Updated Novavax COVID-19 vaccine; Over-the-counter gel for erectile dysfunction; New inserter system for placement of contraceptive intrauterine system.
…
continue reading
1
MPR Weekly Dose Podcast #215 — HIV Drug Discontinuation; Combo for EGFR-Mutated NSCLC; Update on Unapproved Potassium Phosphates in Peds; Otezla Indication Expanded; Tirzepatide Diabetes Risk Reduction ...
12:38
12:38
Spela senare
Spela senare
Listor
Gilla
Gillad
12:38
Genentech decide to remove Fuzeon from US market; Rybrevant and Lazcluze approved as first-line treatment for certain patients with EGFR-mutated advanced NSCLC; FDA warning regarding unapproved potassium phosphates; Otezla approval expanded to include treatment of pediatric patients; Results from tirzepatide diabetes risk reduction study.…
…
continue reading
1
MPR Weekly Dose Podcast #214 — Livdelzi Approved for PBC; Novel Prurigo Nodularis Tx; FDA Denies MDMA Therapy; Yorvipath Approved; Digital Therapy for MDD
14:19
14:19
Spela senare
Spela senare
Listor
Gilla
Gillad
14:19
New Treatment for Primary Biliary Cholangitis; Nemluvio approved for prurigo nodularis; FDA Denies MDMA for PTSD; New hypoparathyroidism treatment; First digital therapeutic approved for depression.
…
continue reading
1
MPR Weekly Dose Podcast #213 — Obesity Drug Shortage Update; Updated Contraceptive Recs; Synovial Sarcoma T-Cell Tx; Lymphir Approved; Fabhalta Gains a New Indication
17:44
17:44
Spela senare
Spela senare
Listor
Gilla
Gillad
17:44
The FDA give an updated on the availability of obesity drugs; The CDC has issued an updated guideline on contraceptive use; The first T-cell gene therapy is approved for synovial sarcoma; Lymphir gains approval for relapsed or refractory cutaneous T-cell lymphoma; Fabhalta gains a new indication.
…
continue reading
1
MPR Weekly Dose Podcast #212 — Compounded Semaglutide Errors; New Alzheimer Disease Tx; Test for Colorectal Cancer; Leqselvi Approved for Alopecia; Palforzia Expanded Approval
14:09
14:09
Spela senare
Spela senare
Listor
Gilla
Gillad
14:09
FDA voice concerns over compounded semaglutide; New treatment approved for mild to moderate dementia of the Alzheimer type; Colorectal cancer screening test gets green light; Leqselvi approved for alopecia; And peanut allergy treatment gains expanded indication.
…
continue reading
1
MPR Weekly Dose Podcast #211 — Duvyzat Available; Device to Treat Nasal Congestion; Pediatric Tx to Delay Diabetes; Soliris Biosimilar; First Orally-Disintegrating Contraceptive
12:16
12:16
Spela senare
Spela senare
Listor
Gilla
Gillad
12:16
Duchenne muscular dystrophy treatment now available; Noise therapy wearable for nasal congestion; Treatment for delaying diabetes gets Fast Tracked; Soliris biosimilar approved; And the first orally-disintegrating contraceptive.
…
continue reading
1
MPR Weekly Dose Podcast #210 — Clonazepam ODT Recall; Parkinson Disease Tx Gets Fast Tracked; Pancreatic CA Vaccine; Voquenzna New Approval; Endari Generic
14:11
14:11
Spela senare
Spela senare
Listor
Gilla
Gillad
14:11
Seizure medication recalled due to wrong strength on carton; Gene therapy gains Fast Track status for Parkinson disease; Dendritic cell vaccine being developed for pancreatic cancer; Generic version of sickle cell disease treatment Endari is made available
…
continue reading
1
MPR Weekly Dose Podcast #209 — Atopic Dermatitis Topical; Wet AMD Implant Available Again; Neurostimulation Device for RA; FDA Denies Weekly Insulin; Smarthphone Therapy for Fibromyalgia
12:56
12:56
Spela senare
Spela senare
Listor
Gilla
Gillad
12:56
New steroid-free topical for atopic dermatitis; A refillable ocular implant for the treatment of neovascular (wet) age-related macular degeneration returns following recall; A neuroimmune modulation device shows clinical benefit in adults with rheumatoid arthritis; FDA denies Novo Nordisk’s once-weekly insulin icodec; And a smarthphone therapy show…
…
continue reading
1
MPR Weekly Dose Podcast #208 — Ohtuvayre Approved; Generic Victoza; DMD Gene Therapy Expanded; Treatment for Pediatric Narcolepsy; OTC Video Game for ADHD
12:21
12:21
Spela senare
Spela senare
Listor
Gilla
Gillad
12:21
New maintenance treatment approved for COPD; Authorized generic version of Victoza launches; Duchenne muscular dystrophy treatment indication expanded; Narcolepsy treatment expanded for certain pediatric patients; FDA clears digital therapeutic for ADHD.
…
continue reading
1
MPR Weekly Dose Podcast #207 — Skyrizi for UC; 21-Valent Pneumococcal Vaccine; Indictment May Affect ADHD Meds; Next-Gen COVID-19 Vaccine; Farxiga Approval Expanded
13:30
13:30
Spela senare
Spela senare
Listor
Gilla
Gillad
13:30
Skyrizi has been approved for ulcerative colitis; New pneumococcal vaccine approved; An indictment may impact as much as 50,000 patients who need ADHD meds; Results announced for Moderna’s next-gen COVID-19 vaccine; Farxiga approval expanded.
…
continue reading
1
MPR Weekly Dose 206 — OTC Glucose Monitors; RSV Vaccine Approval Expanded; Juvenile Idiopathic Arthritis Tx; Emflaza Generic; New Primary Biliary Cholangitis Tx
11:34
11:34
Spela senare
Spela senare
Listor
Gilla
Gillad
11:34
Two glucose monitoring systems have been cleared for over-the-counter sale; Arexvy gains approval for adults aged 50 to 59 years; Kevzara approved for active polyarticular juvenile idiopathic arthritis; Generic Duchenne muscular dystrophy drug is made available; and Iqirvo gets accelerated approval for primary biliary cholangitis.…
…
continue reading
1
MPR Weekly Dose Podcast #205 — Entresto Generics; mRNA-Based RSV Vaccine; Doxycycline PEP for STI Prevention; FDA Vote on MDMA Therapy; Rinvoq Indication Expanded
11:56
11:56
Spela senare
Spela senare
Listor
Gilla
Gillad
11:56
First generics of heart failure drug gain approval; mRNA vaccine approved for RSV; CDC make drug recommendation for STI prevention; Advisory Committee vote on MDMA for PTSD; Rinvoq approval expanded
…
continue reading
1
MPR Weekly Dose 204 — Novel ADHD Extended-Release Tx; Soliris Biosimilar Approved; Depression, Insomnia Tx; FDA Vote on Colorectal CA Test; Mistrust in the FDA
11:49
11:49
Spela senare
Spela senare
Listor
Gilla
Gillad
11:49
Extended-release ADHD treatment gains approval; An interchangeable biosimilar to Soliris is approved; Investigational treatment shows promise for improving depression and insomnia; The FDA vote on a blood-based colorectal cancer diagnostic; Survey reveals public attitudes towards the FDA.
…
continue reading
1
MPR Weekly Dose Podcast 203 — Urinary Incontinence Device; Autoinjector Warning for MS Tx; COVID-19 Preexposure Prophylaxis; Elyea Biosimilars; Lung Cancer Treatment Approved
14:19
14:19
Spela senare
Spela senare
Listor
Gilla
Gillad
14:19
Self-administered device cleared to treat stress urinary incontinence in women; Autoinjector warning for relapsing MS treatment; COVID-19 preexposure prophylaxis investigational treatment looks promising; Biosimilars for Eylea approved; Imdelltra approved for extensive stage small cell lung cancer with disease progression.…
…
continue reading
1
MPR Weekly Dose 202 — Unreliable COVID-19 Tests; Insulin Pump App Update; Noninvasive Colorectal CA Test; Self-Collection HPV Screening Option; Drug Threats to the US
11:09
11:09
Spela senare
Spela senare
Listor
Gilla
Gillad
11:09
Reliability of COVID-19 tests unreliable; Insulin pump app updated following battery issue; Noninvasive colorectal cancer test gets FDA approval; Self-collection HPV screening option; National Drug Threat Assessment highlights illicit drugs currently endangering the US.
…
continue reading
1
Drug Shortage Crisis: An interview with Dr. Michael Ganio
13:54
13:54
Spela senare
Spela senare
Listor
Gilla
Gillad
13:54
Dr. Michael Ganio, ASHP's Director of Pharmacy Practice and Quality, joins me to discuss the current drug shortage crisis, which has reached new levels.
…
continue reading
1
Psilocybin for Depression: An interview with Dr. Charles Raison
28:53
28:53
Spela senare
Spela senare
Listor
Gilla
Gillad
28:53
Dr Charles Raison, the Director of Clinical Research at the Usona Institute and Professor in the Department of Psychiatry at the University of Wisconsin–Madison, joins me to discuss the potential of psilocybin as a therapy for major depressive disorder.
…
continue reading
1
MPR Weekly Dose 199 — Fasenra Expanded Approval; HIV Tx Approval Expanded; ALS Drug Discontinued; CRL for Apomorphine Device; At-Home Mpox Test
11:25
11:25
Spela senare
Spela senare
Listor
Gilla
Gillad
11:25
Asthma treatment gains approval for severe cases in pediatrics; Dovato gains expanded indication; Decision taken to remove ALS drug from market; Complete Response Letter issued for apomorphine device; At-home Mpox test kit made available.
…
continue reading
1
MPR Weekly Dose 198 — Prescription App for MDD; Traumatic Brain Injury Blood Test; New Bloodstream Infection Antibiotic; Mpox Vaccine Availability; Left Ventricular Ejection Fraction Detection
11:40
11:40
Spela senare
Spela senare
Listor
Gilla
Gillad
11:40
First prescription smartphone app approved for major depressive disorder; Novel blood test to detect TBI; Zevtera approved for bloodstream infections; Mpox vaccine is now commercially available; Algorithm cleared for LVEF dectection.
…
continue reading
1
MPR Weekly Dose 197 — Pemgarda Emergency Use; Expansion of Nexletol, Nexlizet; DMD Drug Approval; First Molecular Malaria Blood Test; OTC Topical Analgesic Warning
13:32
13:32
Spela senare
Spela senare
Listor
Gilla
Gillad
13:32
Preexposure prophylaxis approved for COVID-19; Nexletol and Nexlizet gain expanded approval; Novel Duchenne muscular dystrophy treatment; First blood test to screen for malaria in donors; Warning letter for OTC topical analgesic products.
…
continue reading
1
MPR Weekly Dose 196 — Chronic Rhinosinusitis Nasal Spray; Novel hypertension Tx; Stem-Cell Treatment Approved for Rare Disease; Accelerated approval for NASH Tx; Automated Insulin Delivery System
14:10
14:10
Spela senare
Spela senare
Listor
Gilla
Gillad
14:10
Nasal spray approved for chronic rhinosinusitis; Endothelin receptor antagonist gains approval to lower blood pressure in hypertension; One-time stem cell treatment approved for metachromatic leukodystrophy; NASH treatment gains accelerated approval; New automated insulin delivery system for type 1 diabetes.…
…
continue reading
1
MPR Weekly Dose 195 — Weight Loss Tx Gains Cardiovascular Indication; Paxlovid Update; Psilocybin Granted Breakthrough Therapy; Decision Delay for Alzheimer Tx; Relyvrio Trial Results
13:11
13:11
Spela senare
Spela senare
Listor
Gilla
Gillad
13:11
Weight loss treatment has approval expanded; Paxlovid with Emergency Use Authorized label must be disposed of; psychedelic gets Breakthrough therapy designation; Advisory Committee announce meeting to discuss Alzheimer treatment; ALS treatment trial results
…
continue reading
1
MPR Weekly Dose 194 — OTC Birth Control Pill; First OTC Continuous Glucose Monitor; Influenza Vaccine for 2024/2025 Season; Breakthrough Therapy for LSD; Biosimilars to Prolia and Xgeva
13:36
13:36
Spela senare
Spela senare
Listor
Gilla
Gillad
13:36
Over-the-counter birth control pill to be available in the coming weeks; first over-the-counter continuous glucose monitor to be available starting this summer; the 2024-2025 US influenza season vaccine will be trivalent; LSD granted Breakthrough Therapy for treatment of generalized anxiety disorder; interchangeable biosimilars to Prolia and Xgeva …
…
continue reading
1
MPR Weekly Dose 193 — Pepaxto Approval Withdrawn; Abrysvo Efficacy; Ixchiq Vaccine Recommendations; Novel Schizophrenia Tx Decision; UTI Tx Approval; Eye Ointment Recalled
17:01
17:01
Spela senare
Spela senare
Listor
Gilla
Gillad
17:01
FDA withdraw multiple myeloma treatment after a confirmatory trial showed an increased risk of death; latest efficacy results for lower respiratory tract disease vaccine; CDC Chikungunya virus vaccine recommendations; Complete Response Letter issued to investigative schizophrenia treatment; new treatment for complicated UTIs including pyelonephriti…
…
continue reading
1
MPR Weekly Dose 192 — Xolair Approved for Multiple Food Allergies; Amtagvi Gets Approval; Vit D Supplement Recalled; Cannabidiol for Pericarditis; Smartwatch Warning
13:36
13:36
Spela senare
Spela senare
Listor
Gilla
Gillad
13:36
First treatment approved to reduce allergic reactions in those with multiple food allergies; T-cell therapy given accelerated approval to treat unresectable or metastatic melanoma; Vit D supplement recalled due to superpotency; cannabidiol may help resolve the symptoms of pericarditis; FDA warn against certain wearables that claim to measure blood …
…
continue reading
1
MPR Weekly Dose 191 — First FDA-Approved Tx for Frostbite; New Eosinophilic Esophagitis Tx; Psychoactive Accepted for Review for PTSD; Novel Tx for Prurigo Nodularis; OTC Oximeter
14:07
14:07
Spela senare
Spela senare
Listor
Gilla
Gillad
14:07
FDA approves first treatment for severe frostbite; Eohilia gains approval to treat eosinophilic esophagitis; MDMA accepted for Priority Review for PTSD; novel subcutaneous to be reviewed for prurigo nodularis, atopic dermatitis; OTC pulse oximeter device is cleared.
…
continue reading
1
MPR Weekly Dose 190 — Nonopioid Pain Med; Dental Pain Management; Arexvy Review; Magrolimab Development Ended; Athlete’s Foot Spray Recalled
14:37
14:37
Spela senare
Spela senare
Listor
Gilla
Gillad
14:37
Combination intravenous formulation of acetaminophen and ibuprofen approved; recommendations from the ADA for dealing with acute dental pain; RSV vaccine under review for younger adult age group; Gilead call halt on investigational leukemia treatment hagrolimab; athlete foot spray recalled.
…
continue reading
1
MPR Weekly Dose 189 — Alzheimer Drug Discontinued; New Acne Vulgaris Guidelines; Paxlovid Update; ADHD Drug Recall; Safety Alert for Copycat Eye Drops
12:31
12:31
Spela senare
Spela senare
Listor
Gilla
Gillad
12:31
Biogen discontinue Alzheimer treatment; The American Academy of Dermatology issue new acne vulgaris management guidelines; Update for ongoing availability of Paxlovid; Narcolepsy/ADHD treatment recalled for containing wrong drug; FDA warn against copycat eye drop products
…
continue reading
1
MPR Weekly Dose 188 — Labeling Changes for T-Cell Immunotherapies; Novel Opioid Therapy; Boxed Warning for Prolia; At-Home Insemination Kit; Novel Rescue Inhaler
12:57
12:57
Spela senare
Spela senare
Listor
Gilla
Gillad
12:57
T-cell malignancies prompt label changes for certain T-cell immunotherapies; Novel opioid provides in-built protection against overdose; Hypocalcemia risk with Prolia; At-Home semen insemination kit cleared; New asthma rescued medicine approved
…
continue reading
1
MPR Weekly Dose 187 — Gene Therapy for TDT; HyQvia Approved for CIDP; Handheld Skin Assessing Device; Vertebral Strength Device for Low-Bone Mass; Narcan Shelf-Life Extended
13:32
13:32
Spela senare
Spela senare
Listor
Gilla
Gillad
13:32
Gene therapy approved for beta thalassemia; treatment for preventing of chronic inflammatory demyelinating polyneuropathy relapse; device to aid dermatologist referrals; vertebral strength device for low-bone mass; Narcan shelf-life extension
…
continue reading
1
MPR Weekly Dose 186 — Diabetes Tx Suicidal Ideation Link Examined; Topical Molluscum Contagiosum Tx; Superpotent IV Bags Recalled; Syphilis Treatment Update; Menstrual Blood to Measure HbA1c
14:59
14:59
Spela senare
Spela senare
Listor
Gilla
Gillad
14:59
Researchers examine link between diabetes, obesity treatments and suicidal ideation; topical treatment for molluscum contagiosum; IV bags recalled following discovery that they may contain twice as much of the labeled drug; update on the penicillin shortage; newly cleared test measures HbA1c from menstrual blood.…
…
continue reading
1
MPR Weekly Dose 185 — Best Diets for 2024; Counterfeit Ozempic; Myasthenia Gravis Tx Approved; Herpes False Positive Test Results; Promethazine Hydrochloride Safety Concerns
12:28
12:28
Spela senare
Spela senare
Listor
Gilla
Gillad
12:28
An expert panel rank the 30 best diets for 2024; Counterfeit Ozempic on the rise; Myasthenia gravis drug approved; Herpes tests may produce false positives; Safety concerns over IV promethazine hydrochloride.
…
continue reading
1
MPR Weekly Dose 184 — Gel Approved for EB Wounds; 21-Valent Pneumococcal Vaccine; Prescription Game Therapy for ADHD; HIV-Protecting Vaginal Insert; Multiple Food Allergy Drug
16:24
16:24
Spela senare
Spela senare
Listor
Gilla
Gillad
16:24
Topical gel approved to treat partial thickness wounds in epidermolysis bullosa; Priority Review given to 21-valent pneumococcal conjugate vaccine; sensory and motor stimuli video game for ADHD gains expanded age approval; on-demand HIV prevention for women; multiple food allergy drug
…
continue reading
1
MPR Weekly Dose 183 — Updated Diabetes Guidelines; Novel Blood Collection Device; Postpartum Depression Tx; Male Birth Control Study; Approval Sought for Psychoactive Drug
13:31
13:31
Spela senare
Spela senare
Listor
Gilla
Gillad
13:31
The ADA release their new guidance for the management of diabetes 2024; a new blood collection device obtains lab-quality samples using a the finger; novel treatment for postpartum depression becomes available; a study for a male birth control pill begins; and a Public Benefit Corporation seeks approval for an MDMA-assisted therapy.…
…
continue reading
1
MPR Weekly Dose Podcast #182 — Novel Weight Loss Tx; Safety Risks for Compounded Semaglutide; Fabhalta Approved for PNH; At-Home Insemination Kit; Sleep Apnea Device Cleared
14:58
14:58
Spela senare
Spela senare
Listor
Gilla
Gillad
14:58
Novel weight loss treatment now available in pharmacies; Novo Nordisk warns about the risks of compounded semaglutide; treatment approved for paroxysmal nocturnal hemoglobinuria; over-the-counter insemination kit cleared by the FDA.
…
continue reading
1
MPR Weekly Dose Podcast #181 — Serious Reactions to Seizure Treatments; Desmoid Tumor Tx; Secondary CAR T-Cell Malignancies; Immunosuppressive Recall; CPAP Machine Issues
14:36
14:36
Spela senare
Spela senare
Listor
Gilla
Gillad
14:36
Safety alert issued for serious reactions to certain seizure drugs; Drug approved to treat a rare form of tumor; T-cell malignancies reported with cell immunotherapies; organ transplant rejection treatment recalled; CPAP machine associated with reports of burns and fires.
…
continue reading
1
MPR Weekly Dose Podcast #180 — Chikungunya Vaccine; Amazon FDA Warning; At-Home STD Test; Lymphoma Drug Withdrawn; Antimicrobial Catheter Lock Solution for CRBSI
13:57
13:57
Spela senare
Spela senare
Listor
Gilla
Gillad
13:57
First chikungunya vaccine approved; FDA send warning letter to Amazon about ophthalmic products; at-home STD test cleared; Bayer withdraw lymphoma drug; and a combo treatment to reduce catheter-related bloodstream infections is approved.
…
continue reading
1
MPR Weekly Dose Podcast #179 — Weight Management Tx; Levemir Discontinued; Renal Denervation System Approved; Gene Therapy Fasted Tracked; Hidden Drugs in Glucose Supplement
12:44
12:44
Spela senare
Spela senare
Listor
Gilla
Gillad
12:44
New weight management approved; Novo Nordisk discontinue Levemir; adjunctive system for hypertension patients; frontotemporal dementia treatment given Fast Track designation; and the FDA advise against use of glucose supplement.
…
continue reading
1
MPR Weekly Dose Podcast #178 — FDA Flags Eye Drops; Ped Alert for COVID-19 Vaccine; Novel Heartburn Tx; Biosimilar to Stelara Approved; Anti-Fentanyl Monoclonal Antibody
11:53
11:53
Spela senare
Spela senare
Listor
Gilla
Gillad
11:53
FDA urge immediate discontinuation for eye drop products; safety alert issued for the pediatric Moderna COVID-19 vaccine; novel heartburn medicine approved; Stelara biosimilar approved; and an antibody to prevent fentanyl overdose gets fast tracked.
…
continue reading
1
MPR Weekly Dose Podcast 177 — Penbraya Approved; COVID-19 Therapy Shelf-Life Extended; New Formulation for IBD Tx; Self-Admin FluMist; Nonopioid Combo for Postop Pain
11:33
11:33
Spela senare
Spela senare
Listor
Gilla
Gillad
11:33
New pentavalent meningococcal vaccine approved; Gohibic’s shelf-life extended by 6 months; maintenance treatment approved for adults with moderately to severely active ulcerative colitis or Crohn disease; self-administered option for FluMist Quadrivalent accepted for review; intravenous combo formulation of acetaminophen and ibuprofen approved for …
…
continue reading
1
MPR Weekly Dose 176 — Novel MDD Tx; Panel Votes Against ALS Therapy; Preservation-Free Iyuzeh; RSV Vaccine Recommended for During Pregnancy; Investigative Tx Shows Promise in FCS
13:42
13:42
Spela senare
Spela senare
Listor
Gilla
Gillad
13:42
FDA approves a novel treatment for major depressive disorder; vote taken on stem cell therapy for ALS; preservation-free Iyuzeh now available; CDC recommends RSV vaccine for during pregnancy; investigational treatment shows promise in familial chylomicronemia syndrome.
…
continue reading
1
MPR Weekly Dose 175 — Xacduro Now Available; Epinephrine Application Denied; Flu Vaccine Efficacy; New Dosing Regimen for Talicia; Change to Generic Tacrolimus
13:06
13:06
Spela senare
Spela senare
Listor
Gilla
Gillad
13:06
Bacterial pneumonia treatment now available; FDA deny proposed anaphylaxis treatment; Results on flu vaccine efficacy; More flexible dosing for Talicia; Change in the therapeutic equivalence for organ rejection drug generic.
…
continue reading
1
MPR Weekly Dose 174 — Updated COVID-19 Vaccines; Px Drop for Dry Eye Disease; Crohn Disease Tx Trial; Lotronex Update; FDA Cracks Down on Unapproved Eye Products
12:14
12:14
Spela senare
Spela senare
Listor
Gilla
Gillad
12:14
The FDA and CDC greenlight updated COVID-19; prescription drug for dry eye disease now available; head-to-head study comparing Skyrizi to Stelara for Crohn disease; the REMS program has been updated for IBS treatment Lotronex; and the FDA cracks down on companies selling unnaproved eye products.
…
continue reading
1
MPR Weekly Dose Podcast #173 — Talking vaccines with Dr. Abdul-Mutakabbir
30:18
30:18
Spela senare
Spela senare
Listor
Gilla
Gillad
30:18
With fall on the horizon, MPR sat down with Assistant Professor of Clinical Pharmacy at the University of California San Diego, Dr. Abdul-Mutakabbir. Our wide ranging talk covers the updated COVID-19, flu and RSV vaccines. We also discuss vaccine hesitancy, health equity and representation in medicine.…
…
continue reading
1
MPR Weekly Dose 171 — Vaccine Guidance for Flu Season; PrEP Recommendation; Maternal RSV Vaccine; Latest on Updated COVID Vaccine; CHAPLE Disease Tx Approved
18:16
18:16
Spela senare
Spela senare
Listor
Gilla
Gillad
18:16
New vaccine guidelines issued for the 2023-2024 flu season; USPSTF make recommendations on PrEP prescribing; maternal RSV vaccine; updated COVID vaccine shows strong immune response; new treatment approved for rare immune disease.
…
continue reading
1
MPR Weekly Dose 170 — Warning Alert for Tests; Arexy Available for Older Adults; Sohonos and Hezato Kit Approved; Statement on GLP-1 Use Before Endoscopy
15:35
15:35
Spela senare
Spela senare
Listor
Gilla
Gillad
15:35
FDA issue recommendations to avoid Company's tests; RSV vaccine now available for older adults; New treatments approved for fibrodysplasia ossificans progressiva and for those with metastatic uveal melanoma with unresectable hepatic metastases; and gastrointestinal associations issue a statement regarding GLP-1 use prior to upper gastrointestinal e…
…
continue reading